Who are Solid Biosciences Inc.'s main suppliers?

Solid Biosciences Inc. (SLDB) key suppliers include: FA212-LLC, ICS-MAUGERI-S-P-A-SB, UNIVERSITY-OF-PENNSYLVANIA, UNIVERSITY-OF-WASHINGTON, Keros Therapeutics, Inc. and 3 more. View the full supplier network at chainsifter.com/chain/SLDB.

Who are Solid Biosciences Inc.'s major customers?

Solid Biosciences Inc. (SLDB) key customers include: Insmed Incorporated, Insmed Incorporated, Lexeo Therapeutics, Inc., Myriad Genetics, Inc., Myriad Genetics, Inc. and 11 more. View the full customer network at chainsifter.com/chain/SLDB.

What sector is Solid Biosciences Inc. in?

Solid Biosciences Inc. (SLDB) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Solid Biosciences Inc. Supplier List (SLDB): 8 Verified Suppliers

8Suppliers

16Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

Solid Biosciences Inc. (SLDB) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

27Total relationships

2Distinct source URLs

7High confidence

0.734Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Solid Biosciences Inc. Suppliers

Ticker	Name	Confidence	Evidence
FA212-LLC	FA212-LLC	92%	The Company entered into an asset purchase agreement with FA212 LLC for the purchase of certain intellectual property, including patents and assigned licenses related to a preclinical drug candidate,…
ICS-MAUGERI-S-P-A-SB	ICS-MAUGERI-S-P-A-SB	90%	We paid Maugeri an upfront license fee of €1.5 million, which was recorded as research and development expense during the second quarter of 2023.
UNIVERSITY-OF-PENNSYLVANIA	UNIVERSITY-OF-PENNSYLVANIA	90%	The Company also assumed from FA212 contingent development milestone payments of up to $ 4.2 million, regulatory milestone payments of up to $ 13.0 million, cumulative sales milestone payments of up …
UNIVERSITY-OF-WASHINGTON	UNIVERSITY-OF-WASHINGTON	80%	In 2015, we entered into a license agreement with the University of Washington, acting through UW CoMotion, under which we obtained an exclusive, royalty-bearing, sublicensable, worldwide license und…
KROS	Keros Therapeutics, Inc.	72%	Reciprocal relationship from KROS graph: Reciprocal relationship from SLDB graph: Reciprocal relationship from KROS graph: Reciprocal relationship from SLDB graph: Reciprocal relationship from KROS g…
LXEO	Lexeo Therapeutics, Inc.	72%	Reciprocal relationship from LXEO graph: Reciprocal relationship from SLDB graph: Reciprocal relationship from LXEO graph: Reciprocal relationship from SLDB graph: Reciprocal relationship from LXEO g…
RARE	Ultragenyx Pharmaceutical Inc.	72%	Reciprocal relationship from RARE graph: Reciprocal relationship from SLDB graph: Reciprocal relationship from RARE graph: ch was subsequently amended, with Baylor Research Institute, or BRI, under w…
TRDA	Entrada Therapeutics, Inc.	72%	Reciprocal relationship from TRDA graph: f treatment with our therapeutics in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-party coverage an…

Solid Biosciences Inc. Customers

Ticker	Name	Confidence	Evidence
INSM	Insmed Incorporated	72%	components in sufficient quantity and in a timely manner due to disruptions in the global supply chain caused by macroeconomic events and conditions, the development, testing and clinical trials of o…
INSM	Insmed Incorporated	72%	Reciprocal relationship from INSM graph: Reciprocal relationship from SLDB graph: Reciprocal relationship from INSM graph: Reciprocal relationship from SLDB graph: components in sufficient quantity a…
LXEO	Lexeo Therapeutics, Inc.	72%	Reciprocal relationship from LXEO graph: ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reaso…
MYGN	Myriad Genetics, Inc.	72%	Reciprocal relationship from MYGN graph: Reciprocal relationship from SLDB graph: tain of our in-licensed U.S. patent rights lack corresponding foreign patents or patent applications, and therefore w…
MYGN	Myriad Genetics, Inc.	72%	tain of our in-licensed U.S. patent rights lack corresponding foreign patents or patent applications, and therefore we will be unable to obtain patent protection for our Candidates in certain jurisdi…
SRPT	Sarepta Therapeutics, Inc.	72%	Reciprocal relationship from SRPT graph: Reciprocal relationship from SLDB graph: components in sufficient quantity and in a timely manner due to disruptions in the global supply chain caused by macr…
SRPT	Sarepta Therapeutics, Inc.	72%	components in sufficient quantity and in a timely manner due to disruptions in the global supply chain caused by macroeconomic events and conditions, the development, testing and clinical trials of o…
TRDA	Entrada Therapeutics, Inc.	72%	Reciprocal relationship from TRDA graph: everal risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for sub…
CARDURION-PHARMACEUTICALS-INC	CARDURION-PHARMACEUTICALS-INC	62%	components in sufficient quantity and in a timely manner due to disruptions in the global supply chain caused by macroeconomic events and conditions, the development, testing and clinical trials of o…
CHEVRON-U-S-A-INC	CHEVRON-U-S-A-INC	62%	the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the European Union’s requirements regarding the protection of personal information can …
CORNER-POST-INC	CORNER-POST-INC	62%	the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the European Union’s requirements regarding the protection of personal information can …
DELAWARE-GENERAL-CORPORATION	DELAWARE-GENERAL-CORPORATION	62%	tent protection afforded could be less than we request. In addition, to the extent we wish to pursue patent term extension based on a patent that we in-license from a third party, we would need the c…
FA212-LLC	FA212-LLC	62%	. Recently Adopted Accounting Pronouncements In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” This ASU updates income tax disclos…
NATURAL-RESOURCES-DEFENSE-COUNCIL-INC	NATURAL-RESOURCES-DEFENSE-COUNCIL-INC	62%	the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the European Union’s requirements regarding the protection of personal information can …
PLAB	Photronics, Inc.	62%	Reciprocal relationship from PLAB graph: Reciprocal relationship from SLDB graph: tain of our in-licensed U.S. patent rights lack corresponding foreign patents or patent applications, and therefore w…
PROMETHEUS-LABORATORIES-INC	PROMETHEUS-LABORATORIES-INC	62%	tain of our in-licensed U.S. patent rights lack corresponding foreign patents or patent applications, and therefore we will be unable to obtain patent protection for our Candidates in certain jurisdi…

Solid Biosciences Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
SLDB-DEBT	Debt stack $20.7M	90%	Market cache reports total debt of $20.7M.
SLDB-DEBT-12575	Warrants outstanding: 49.35	90%	xbrl warrant detail from xbrl 2025-12-31.

Solid Biosciences Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Solid Biosciences Inc..

Solid Biosciences Inc. Ownership

Holder	Name	Confidence	Evidence
SLDB-OWNER-PERCEPTIVE-ADVISORS-LLC	PERCEPTIVE ADVISORS LLC	90%	13F overlay lists PERCEPTIVE ADVISORS LLC as top holder; 142 tracked holders.

Solid Biosciences Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
ATYR	aTyr Pharma, Inc.	100.00	2
IMNM	Immunome, Inc.	100.00	2
ELVN	Enliven Therapeutics, Inc.	100.00	2
CPRX	Catalyst Pharmaceuticals, Inc.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
BIAF	bioAffinity Technologies, Inc.	100.00	2
BNTC	Benitec Biopharma Inc.	100.00	2
BNBX	BNB Plus Corp.	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
ALLO	Allogene Therapeutics, Inc.	100.00	2
PSNL	Personalis, Inc.	100.00	2
RGNX	REGENXBIO Inc.	100.00	2
DYN	Dyne Therapeutics, Inc.	100.00	2
ARWR	Arrowhead Pharmaceuticals, Inc.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	2
CABA	Cabaletta Bio, Inc.	100.00	2
CALC	CalciMedica, Inc.	100.00	2
BMRN	BioMarin Pharmaceutical Inc.	100.00	2
HOWL	Werewolf Therapeutics, Inc.	100.00	2

Solid Biosciences Inc. Supply Chain